Research programme: anti-cancer therapeutics - Theryte

Alternative Names: THR-53; THR-93

Latest Information Update: 06 Jul 2016

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator TheRyte Ltd
Class Peptidomimetics
Mechanism of Action CDC2 protein kinase modulators; Cyclin-dependent kinase 4 modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Cancer

Highest Development Phases

Preclinical Non-small cell lung cancer

Most Recent Events

06 Jul 2016 Preclinical development is ongoing in United Kingdom
06 Jul 2016 Anti-cancer therapeutics are available for licensing as of 06 Jul 2016. http://www.theryte.com/

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.